Amniotic fluid and amniotic membrane are young, immune privileged tissues rich with pluripotent and multipotent stem cells, as well as a full range of growth factors and supporting collagen,  proteins, carbohydrates, keratinocytes, and cytokines.  For these reasons amnion-derived therapies have shown much promise in a number of surgical procedures by taking a regenerative approach.  Clinical success has been well documented to date.  Both physicians and researchers alike continue their efforts to unlock the full potential of amnion-derived allografts.  The superior anti-fibrotic/anti-adhesive properties of amniotic membrane have proven useful in preventing adhesions and scarring in cardiothoratic surgery. 

Click to View NIH Study:  Effect Of Human Amniotic Fluid On Bone Healing

Improving Outcomes with Amnio Technology

Amnion-derived allografts have been an effective modality to reduce scarring, minimize risk of adhesions, and heal tissue faster after surgery.  Amnion-derived therapies work by releasing various healing factors as well as recruiting stem cells to the site of damage to promote tissue regeneration.  Stem cells are primitive cells that can undergo differentiation to form different types of cells in the body, such as bone, blood, cartilage, tendon, ligaments, etc. These cells are responsible for healing tissue damages by generating new healthy cells. However, with age, the body loses its ability to attract enough stem cells to the site of injury. In this regard, amnio therapy delivers a high concentration of proteins, carbohydrates, cytokines, keratinocytes and growth factors to feed stem cells at the affected area to promote rapid, natural healing.